Ho Wah unit gets FDA nod for vaccine trials

With the FDA approval, HWGB chief executive officer Datuk Aaron Lim (pic) said the repurposing of the proven polio virus vaccines could fast track the Covid-19 vaccine development to save lives

PETALING JAYA: US-based E-MO Biology Inc, the joint-venture partner of Ho Wah Genting Bhd’s (HWGB) wholly-owned subsidiary, HWGB Biotech Sdn Bhd, has obtained approval from the US Food and Drug Administration (FDA) to conduct phase IV clinical trials for a vaccine against Covid-19.

In a statement, HWGB said HWGB Biotech would invest US$1mil (RM4.16mil) and would be entitled to 40% of the total net profit.